Larimar Therapeutics (LRMR) Accounts Payables (2013 - 2025)

Larimar Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $5.2 million for Q4 2025.

• Quarterly Accounts Payables rose 115.18% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (up 115.18% YoY) and the FY2025 annual result came in at $5.2 million, up 115.18% from the prior year.
• Accounts Payables was $5.2 million for Q4 2025 at Larimar Therapeutics, down from $11.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.1 million in Q3 2025 and bottomed at $425000.0 in Q2 2022.
• A 5-year average of $2.5 million and a median of $1.8 million in 2021 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables surged 903.11% — and 2023, when it plunged 71.25%.
• Larimar Therapeutics' Accounts Payables stood at $1.7 million in 2021, then gained by 1.57% to $1.7 million in 2022, then fell by 23.9% to $1.3 million in 2023, then soared by 88.93% to $2.4 million in 2024, then surged by 115.18% to $5.2 million in 2025.
• Business Quant data shows LRMR's Accounts Payables at $5.2 million in Q4 2025, $11.1 million in Q3 2025, and $4.2 million in Q2 2025.